Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5763-5771

  Senzer, Neil N ^a   Kaufman, Howard L ^a   Amatruda, Thomas ^a   Nemunaitis, Mike ^a   Reid, Tony ^a   Daniels, Gregory ^a   Gonzalez, Rene ^a   Glaspy, John ^a   Whitman, Eric ^a   Harrington, Kevin ^a   Goldsweig, Howard ^a   Marshall, Tracey ^a   Love, Colin ^a   Coffin, Robert ^a   Nemunaitis, John J ^a  

^a Mountainside Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TEMOZOLOMIDE;

ANTIBODY RESPONSE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HERPES VIRUS; HUMAN; MALE; MELANOMA; METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS SHEDDING; ADULT; AGED; HERPES SIMPLEX VIRUS 1; INTRALESIONAL DRUG ADMINISTRATION; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; PATHOLOGY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MELANOMA; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; SKIN NEOPLASMS;

EID: 73349133717     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.3675     Document Type: Article

References (22)

1. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
2. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 22:1118-1125, 2004
3. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745, 2006
4. Gogas HJ, Kirkwood JM, Sondak VK: Chemotherapy for metastatic melanoma: Time for a change? Cancer 109:455-464, 2007
5. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
6. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915, 2004
7. Riker AI, Sondak VK, Fishman M, et al: Current immunotherapy of melanoma. Clin Appl Immunol Rev 5:111-132, 2005
8. Faries MB: Evaluation of immunotherapy in the treatment of melanoma. Surg Oncol Clin N Am 15:399-418, 2006
9. Farray D, Clark JI: Vaccine therapy of malignant melanoma. Clin Appl Immunol Rev 6:217-230, 2006
10. Riker AI, Radfar S, Liu S, et al: Immunotherapy of melanoma: A critical review of current concepts and future strategies. Expert Opin Biol Ther 7:345-358, 2007
11. Ralph SJ: An update on malignant melanoma vaccine research: Insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines. Am J Clin Dermatol 8:123-141, 2007
12. Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008
13. Liu BL, Robinson M, Han ZQ, et al: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10:292-303, 2003
14. Hu JC, Coffin RS, Davis CJ, et al: A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12:6737-6747, 2006
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Hamid O, Urba WJ, Yellin MJ, et al: Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. J Clin Oncol 25:18S, 2007 (suppl; abstr 8525)
17. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
18. Farassati F, Yang AD, Lee PW: Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3:745-750, 2001
19. Sarinella F, Calistri A, Sette P, et al: Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther 13:1080-1087, 2006
20. Toda M, Rabkin SD, Kojima H, et al: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10:385-393, 1999
21. Chahlavi A, Rabkin S, Todo T, et al: Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6:1751-1758, 1999
22. Hodi FS, Hoos A, Ibrahim R, et al: Novel efficacy criteria for antitumor activity using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol 26:134S, 2008 (suppl; abstr 3008)